Lv61
2180 积分 2022-04-29 加入
Red Blood Cells: A Neglected Compartment in Pharmacokinetics and Pharmacodynamics
29天前
已完结
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
1个月前
已完结
LPA Receptors: Subtypes and Biological Actions
1个月前
已完结
Novel Cyclohexyl Amido Acid Antagonists of Lysophosphatidic Acid Type 1 Receptor for the Treatment of Pulmonary Fibrosis
1个月前
已完结
Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases
1个月前
已完结
Evidence from recent clinical trials in fibrotic interstitial lung diseases
1个月前
已完结
The development of modulators for lysophosphatidic acid receptors: A comprehensive review
1个月前
已完结
BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study
1个月前
已关闭
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278
1个月前
已完结
Mechanisms of Lactoferrin‐induced Leukocyte‐Endothelial Cell Adhesion in Postcapillary Venules
1个月前
已完结
皖公网安备34019202002308
